International Journal of Clinical Research

Objective To compare the efficacy and safety of tirofiban and argatroban as monotherapy in patients with acute ischemic cerebral infarction (AIS) within the superthrombolysis time window (9-72 hours). Methods Sixty patients with superthrombolysis time window AIS admitted to our hospital from March 2023 to March 2024 were selected and divided into two groups by random number table method. Both groups were given basic treatment. The observation group was added with tirofiban antiplatelet, and the control group was added with argatroban anticoagulation. The neurological functions, activities of daily living, drug onset and the best prognosis time of the two groups were compared, and the occurrence of adverse reactions was analyzed. Results The onset time of the drug in the observation group was shorter than that in the control group, and the improvement amplitudes of NIHSS and ADL scores were better than those in the control group (P<0.05). There was no significant difference in the good prognosis rate and the incidence of bleeding adverse reactions between the two groups of mRS (P>0.05). Conclusion Tirofiban monotherapy shows a faster improvement in neurological function for cerebral infarction within the superthrombolysis time window. Argatroban monotherapy has a stable safety performance. Clinically, medication can be selected based on the risk of thrombosis and bleeding tendency.

Tirofiban; Argatroban; Superthrombolysis time window; AIS